Acute Coronary Syndrome: Secondary Prevention | Disease Landscape & Forecast | G7 | 2024
Acute coronary syndrome (ACS) encompasses acute ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina. ACS is a significant cause of morbidity and mortality in developed countries. The therapy market is divided into the acute hospital setting and the post-hospital secondary prevention setting. This report focuses on the 12-month post-hospital secondary prevention market. The post-ACS market is currently dominated by oral antiplatelet agents, statins, beta blockers, and angiotensin pathway modulators. Despite optimal therapy, the risk of recurrent ischemic events in post-ACS patients remains high. The identification of new risk factors and potential targets has led to new opportunities for pharmaceutical companies to develop drugs that address the limitations of current treatments. Indeed, the forecast period is expected to see the launch of novel lipid-lowering and antithrombotic agents aimed at further reducing the risk of cardiovascular events and disease progression.
Questions answered
- What factors will drive and constrain the growth of the ACS secondary prevention market?
- How will the market evolve over the next 10 years?
- What is the commercial potential of the Lp(a) inhibitors pelacarsen and olpasiran, the PCSK9 inhibitor inclisiran (Leqvio), and the FXIa inhibitor milvexian?
- How do leaders in the field of ACS management rate the novel therapies targeting Lp(a) and inflammation?
- To which patients do physicians currently prescribe the PCSK9 inhibitors? What is their opinion on the future of this class in the secondary prevention of ACS?
Geography
United States, EU5, Japan
Primary research
17 country-specific interviews with thought-leading cardiologists; supported by survey data collected for this and other Clarivate research
Epidemiology
12-month diagnosed prevalent cases of ACS by country and subtype
Forecast
10-year, annualized, drug-level sales and patient share of key ACS secondary prevention therapies through 2033, segmented by brands / generics
Drug treatments
Coverage of key current and emerging therapies
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
